|
|
|
|
| LEADER |
00000cam a2200000Ia 4500 |
| 001 |
EBSCO_ocn559734779 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr cn||||||||| |
| 008 |
910211s1991 dcu ob 100 0 eng d |
| 010 |
|
|
|a 91060585
|
| 040 |
|
|
|a MERUC
|b eng
|e pn
|c MERUC
|d CCO
|d E7B
|d OCLCQ
|d UV0
|d CASUM
|d DKDLA
|d OCLCE
|d IDEBK
|d CUS
|d XFF
|d OCLCQ
|d ORU
|d OCLCQ
|d N$T
|d YDXCP
|d COF
|d OCLCO
|d FVL
|d OCLCQ
|d NLGGC
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCQ
|d AZK
|d TOA
|d COCUF
|d AGLDB
|d MNU
|d SUR
|d MOR
|d PIFBR
|d OCLCQ
|d OCLCA
|d U3W
|d OCLCA
|d BUF
|d OCLCO
|d GILDS
|d OCLCF
|d OCLCO
|d VNS
|d OCLCO
|d OCLCQ
|d VTS
|d LVT
|d VT2
|d STF
|d WRM
|d NRAMU
|d INT
|d XFH
|d EBLCP
|d ZCU
|d ICG
|d OCLCQ
|d N$T
|d OCLCO
|d AU@
|d OCLCQ
|d OCLCO
|d OCLCA
|d DKC
|d OCLCO
|d OCLCQ
|d ADU
|d KIJ
|d OCLCA
|d INARC
|d AJS
|d OCLCA
|d OCLCO
|d OCLCQ
|
| 019 |
|
|
|a 44954780
|a 228064206
|a 245535671
|a 475709283
|a 551505442
|a 629930493
|a 642456878
|a 647353775
|a 666933634
|a 722242379
|a 728013566
|a 814274466
|a 923259948
|a 961669896
|a 961673586
|a 962592044
|a 962635940
|a 972040095
|a 975242794
|a 975293706
|a 982314368
|a 984884368
|a 988438325
|a 990088987
|a 992114622
|a 994555841
|a 1003586155
|a 1016139292
|a 1017678387
|a 1018073288
|a 1021259647
|a 1058117548
|a 1112848367
|a 1118983063
|a 1119024608
|a 1156404089
|a 1162131089
|a 1175669579
|a 1182015092
|a 1193130606
|a 1204385213
|a 1228541956
|
| 020 |
|
|
|a 058515547X
|q (electronic bk.)
|
| 020 |
|
|
|a 9780585155470
|q (electronic bk.)
|
| 020 |
|
|
|z 1280203560
|
| 020 |
|
|
|z 9781280203565
|
| 020 |
|
|
|z 9780309583367
|
| 020 |
|
|
|z 0309583365
|
| 020 |
|
|
|z 0309044901
|q (pbk.)
|
| 020 |
|
|
|z 9780309044905
|q (pbk.)
|
| 029 |
1 |
|
|a AU@
|b 000050961285
|
| 029 |
1 |
|
|a AU@
|b 000051481802
|
| 029 |
1 |
|
|a DEBBG
|b BV043067348
|
| 029 |
1 |
|
|a DEBBG
|b BV044106699
|
| 029 |
1 |
|
|a DEBSZ
|b 422565784
|
| 029 |
1 |
|
|a GBVCP
|b 80307994X
|
| 029 |
1 |
|
|a NZ1
|b 11927890
|
| 029 |
1 |
|
|a NZ1
|b 16094530
|
| 029 |
1 |
|
|a DKDLA
|b 820120-katalog:999925692905765
|
| 029 |
1 |
|
|a AU@
|b 000068179769
|
| 035 |
|
|
|a (OCoLC)559734779
|z (OCoLC)44954780
|z (OCoLC)228064206
|z (OCoLC)245535671
|z (OCoLC)475709283
|z (OCoLC)551505442
|z (OCoLC)629930493
|z (OCoLC)642456878
|z (OCoLC)647353775
|z (OCoLC)666933634
|z (OCoLC)722242379
|z (OCoLC)728013566
|z (OCoLC)814274466
|z (OCoLC)923259948
|z (OCoLC)961669896
|z (OCoLC)961673586
|z (OCoLC)962592044
|z (OCoLC)962635940
|z (OCoLC)972040095
|z (OCoLC)975242794
|z (OCoLC)975293706
|z (OCoLC)982314368
|z (OCoLC)984884368
|z (OCoLC)988438325
|z (OCoLC)990088987
|z (OCoLC)992114622
|z (OCoLC)994555841
|z (OCoLC)1003586155
|z (OCoLC)1016139292
|z (OCoLC)1017678387
|z (OCoLC)1018073288
|z (OCoLC)1021259647
|z (OCoLC)1058117548
|z (OCoLC)1112848367
|z (OCoLC)1118983063
|z (OCoLC)1119024608
|z (OCoLC)1156404089
|z (OCoLC)1162131089
|z (OCoLC)1175669579
|z (OCoLC)1182015092
|z (OCoLC)1193130606
|z (OCoLC)1204385213
|z (OCoLC)1228541956
|
| 042 |
|
|
|a dlr
|
| 043 |
|
|
|a n-us---
|
| 050 |
|
4 |
|a RC607.A26
|b N53 1991eb
|
| 060 |
|
4 |
|a WD 308
|b N617e 1991
|
| 072 |
|
7 |
|a MED
|x 022020
|2 bisacsh
|
| 072 |
|
7 |
|a HEA
|x 039020
|2 bisacsh
|
| 072 |
|
7 |
|a MJCJ2
|2 bicssc
|
| 082 |
0 |
4 |
|a 362.1/969792/00973
|2 20
|
| 049 |
|
|
|a UAMI
|
| 100 |
1 |
|
|a Nichols, Eve K.
|
| 245 |
1 |
0 |
|a Expanding access to investigational therapies for HIV infection and AIDS :
|b March 12-13, 1990, conference summary /
|c Eve Nichols [writer] ; Roundtable for the Development of Drugs and Vaccines against AIDS, Institute of Medicine.
|
| 260 |
|
|
|a Washington, D.C. :
|b National Academy Press,
|c 1991.
|
| 300 |
|
|
|a 1 online resource (viii, 73 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a data file
|2 rda
|
| 504 |
|
|
|a Includes bibliographical references.
|
| 588 |
0 |
|
|a Print version record.
|
| 506 |
|
|
|3 Use copy
|f Restrictions unspecified
|5 MiAaHDL
|2 star
|
| 533 |
|
|
|a Electronic reproduction.
|b [S.l.] :
|c HathiTrust Digital Library,
|d 2010.
|5 MiAaHDL
|
| 538 |
|
|
|a Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002.
|u http://purl.oclc.org/DLF/benchrepro0212
|5 MiAaHDL
|
| 583 |
1 |
|
|a digitized
|c 2010
|h HathiTrust Digital Library
|l committed to preserve
|5 MiAaHDL
|2 pda
|
| 505 |
0 |
|
|a ""Expanding Access to Investigational Therapies for HIV Infection and AIDS""; ""Copyright""; ""PREFACE""; ""Contents""; ""EXPANDING ACCESS TO INVESTIGATIONAL THERAPIES FOR HIV INFECTION AND AIDS""; ""Expanding Access to Investigational Therapies March 12�13, 1990 Program""; ""1 HISTORICAL PERSPECTIVE""; ""EARLY DEVELOPMENT OF EXPANDED ACCESS""; ""Drug Amendments of 1962""; ""Access for Therapeutic Purposes""; ""Growing Confusion""; ""Modern Clinical Trials (Non-AIDS Drugs)""; ""THE ADVENT OF AIDS""; ""Broadening Participation""; ""Accelerating the Pace of Drug Development""
|
| 505 |
8 |
|
|a ""Improving Response Capabilities""""Expedited Development""; ""Expanded Access""; ""Treatment Investigational New Drugs""; ""Parallel Track""; ""2 RIGHTS AND RESPONSIBILITIES""; ""FREEDOM OF CHOICE""; ""INFORMED CONSENT""; ""Information Resources""; ""Access""; ""Primary Care""; ""Difficult Choices""; ""COMPETING RIGHTS""; ""INSTITUTIONAL REVIEW BOARDS""; ""NEW ATTITUDES""; ""3 EVALUATION OF EXPANDED ACCESS PROGRAMS""; ""TREATMENT INVESTIGATIONAL NEW DRUGS""; ""POTENTIAL RISKS""; ""Examples from the Past""; ""The Target Population""; ""Safety Data""
|
| 505 |
8 |
|
|a ""IMPACT ON CONVENTIONAL RANDOMIZED TRIALS""""THE PARALLEL TRACK EXPERIMENT""; ""4 CREATIVITY IN CLINICAL TRIALS""; ""THE CHANGING ENVIRONMENT""; ""CONVENTIONAL TRIALS""; ""PREFERENCE TRIALS""; ""LARGE, SIMPLE RANDOMIZED TRIALS""; ""Physician Participation""; ""Quality Control""; ""DATA FROM THE PARALLEL TRACK""; ""Efficacy Data""; ""Safety Data and Related Information""; ""Expectations""; ""5 DRUG INNOVATION AND THE PHARMACEUTICAL INDUSTRY""; ""TIME TO COMMERCIALIZATION""; ""DIRECT COSTS OF EXPANDED ACCESS""; ""Manpower Needs""; ""Drug Costs""; ""The Small Manufacturer""
|
| 505 |
8 |
|
|a ""PRODUCT LIABILITY""""Concerns Specific to the Parallel Track""; ""Potential Solutions""; ""6 THIRD-PARTY PAYERS""; ""BLUE CROSS AND BLUE SHIELD""; ""HEALTH INSURANCE ASSOCIATION OF AMERICA""; ""HEALTH CARE FINANCING ADMINISTRATION""; ""Medicaid""; ""State Discretion""; ""Patient Care Costs""; ""Medicare""; ""RESOURCES FOR CLINICAL INVESTIGATION""; ""7 IMPROVING ACCESS TO CARE""; ""PEOPLE OF COLOR""; ""Resource Considerations""; ""Suspicion""; ""Informed Consent""; ""WOMEN""; ""The Gender Perspective""; ""Risk Factors""; ""Protocol Development""; ""Women as Vectors""; ""A New Approach""
|
| 505 |
8 |
|
|a ""THE PEDIATRIC POPULATION""""Scientific Issues""; ""Social Issues""
|
| 546 |
|
|
|a English.
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a AIDS (Disease)
|x Chemotherapy
|x Social aspects
|z United States
|v Congresses.
|
| 650 |
|
0 |
|a Pharmacology, Experimental
|x Social aspects
|z United States
|v Congresses.
|
| 650 |
|
0 |
|a HIV infections
|x Chemotherapy
|x Social aspects
|z United States
|v Congresses.
|
| 650 |
|
0 |
|a Institutional review boards (Medicine)
|
| 650 |
|
0 |
|a Health services accessibility.
|
| 650 |
|
0 |
|a Social control.
|
| 650 |
|
0 |
|a AIDS (Disease)
|
| 650 |
|
0 |
|a Children.
|
| 650 |
|
0 |
|a Federal government.
|
| 650 |
|
0 |
|a Human experimentation in medicine.
|
| 650 |
|
0 |
|a Research.
|
| 650 |
|
0 |
|a Risk.
|
| 650 |
|
0 |
|a HIV infections.
|
| 650 |
|
0 |
|a Risk assessment.
|
| 650 |
|
0 |
|a Ethics committees.
|
| 650 |
|
0 |
|a Liberty.
|
| 650 |
|
0 |
|a Information services.
|
| 650 |
|
0 |
|a Women.
|
| 650 |
|
0 |
|a Medical care.
|
| 650 |
|
0 |
|a Informed consent (Medical law)
|
| 650 |
|
0 |
|a Minorities.
|
| 650 |
|
0 |
|a Pharmaceutical industry.
|
| 650 |
|
0 |
|a Methodology.
|
| 650 |
|
0 |
|a Economics.
|
| 650 |
|
0 |
|a Human rights.
|
| 650 |
|
0 |
|a Sociology.
|
| 650 |
|
0 |
|a Probabilities.
|
| 650 |
|
0 |
|a Industries.
|
| 650 |
|
0 |
|a Slow virus diseases.
|
| 650 |
|
0 |
|a Non-governmental organizations.
|
| 650 |
|
0 |
|a Science.
|
| 650 |
|
0 |
|a National health services.
|
| 650 |
|
0 |
|a Drugs.
|
| 650 |
|
0 |
|a Health services administration.
|
| 650 |
|
0 |
|a Communication.
|
| 650 |
|
0 |
|a Immunological deficiency syndromes.
|
| 650 |
|
0 |
|a Risk management.
|
| 650 |
|
0 |
|a Lentivirus infections.
|
| 650 |
|
0 |
|a Social sciences.
|
| 650 |
|
0 |
|a Insurance.
|
| 650 |
|
0 |
|a Therapeutics.
|
| 650 |
|
0 |
|a Medical care
|x Quality control.
|
| 650 |
|
0 |
|a Statistics.
|
| 650 |
|
0 |
|a Public health.
|
| 650 |
|
0 |
|a Physical sciences.
|
| 650 |
|
0 |
|a Humanities.
|
| 650 |
|
0 |
|a Sexually transmitted diseases.
|
| 650 |
|
0 |
|a Virus diseases.
|
| 650 |
|
2 |
|a Ethics Committees, Research
|
| 650 |
|
2 |
|a Government Regulation
|
| 650 |
|
2 |
|a Health Services Accessibility
|
| 650 |
|
2 |
|a Personal Autonomy
|
| 650 |
|
2 |
|a Public Policy
|
| 650 |
|
2 |
|a Random Allocation
|
| 650 |
|
2 |
|a Research Design
|
| 650 |
|
2 |
|a Social Control, Formal
|
| 650 |
|
2 |
|a HIV Seropositivity
|
| 650 |
|
2 |
|a Acquired Immunodeficiency Syndrome
|
| 650 |
|
2 |
|a Child
|
| 650 |
|
2 |
|a Federal Government
|
| 650 |
|
2 |
|a Human Experimentation
|
| 650 |
|
2 |
|a Information Dissemination
|
| 650 |
|
2 |
|a Patient Selection
|
| 650 |
|
2 |
|a Research
|
| 650 |
|
2 |
|a Risk
|
| 650 |
|
2 |
|a Socioeconomic Factors
|
| 650 |
|
2 |
|a Government
|
| 650 |
|
2 |
|a HIV Infections
|
| 650 |
|
2 |
|a Insurance, Health
|
| 650 |
|
2 |
|a Risk Assessment
|
| 650 |
|
2 |
|a Ethics Committees
|
| 650 |
|
2 |
|a Freedom
|
| 650 |
|
2 |
|a Information Services
|
| 650 |
|
2 |
|a Therapeutic Human Experimentation
|
| 650 |
|
2 |
|a Women
|
| 650 |
|
2 |
|a Clinical Trials as Topic
|
| 650 |
|
2 |
|a Patient Care
|
| 650 |
|
2 |
|a Vulnerable Populations
|
| 650 |
|
2 |
|a Informed Consent
|
| 650 |
|
2 |
|a Research Subjects
|
| 650 |
|
2 |
|a Minority Groups
|
| 650 |
|
2 |
|a Drugs, Investigational
|
| 650 |
|
2 |
|a Drug Industry
|
| 650 |
|
2 |
|a Financial Support
|
| 650 |
|
2 |
|a Health Care Economics and Organizations.
|
| 650 |
|
2 |
|a Methods
|
| 650 |
|
2 |
|a Economics
|
| 650 |
|
2 |
|a Human Rights
|
| 650 |
|
2 |
|a Sociology
|
| 650 |
|
2 |
|a Probability
|
| 650 |
|
2 |
|a Industry
|
| 650 |
|
2 |
|a Principle-Based Ethics
|
| 650 |
|
2 |
|a Slow Virus Diseases
|
| 650 |
|
2 |
|a Ethics
|
| 650 |
|
2 |
|a Epidemiologic Study Characteristics as Topic.
|
| 650 |
|
2 |
|a Professional Staff Committees
|
| 650 |
|
2 |
|a Organizations
|
| 650 |
|
2 |
|a Evaluation Studies as Topic
|
| 650 |
|
2 |
|a Psychological Phenomena and Processes.
|
| 650 |
|
2 |
|a Jurisprudence
|
| 650 |
|
2 |
|a Social Control Policies
|
| 650 |
|
2 |
|a Delivery of Health Care
|
| 650 |
|
2 |
|a Patient Rights
|
| 650 |
|
2 |
|a Science
|
| 650 |
|
2 |
|a Persons.
|
| 650 |
|
2 |
|a Health Services
|
| 650 |
|
2 |
|a Epidemiologic Research Design
|
| 650 |
|
2 |
|a Pharmaceutical Preparations
|
| 650 |
|
2 |
|a Patient Care Management
|
| 650 |
|
2 |
|a Population Characteristics
|
| 650 |
|
2 |
|a Communication
|
| 650 |
|
2 |
|a Age Groups.
|
| 650 |
|
2 |
|a Sexually Transmitted Diseases, Viral
|
| 650 |
|
2 |
|a Immunologic Deficiency Syndromes
|
| 650 |
|
2 |
|a Risk Management
|
| 650 |
|
2 |
|a Epidemiologic Measurements
|
| 650 |
|
2 |
|a Lentivirus Infections
|
| 650 |
|
2 |
|a Social Sciences
|
| 650 |
|
2 |
|a Information Science
|
| 650 |
|
2 |
|a Biomedical Research
|
| 650 |
|
2 |
|a Insurance
|
| 650 |
|
2 |
|a Investigative Techniques.
|
| 650 |
|
2 |
|a Therapeutics
|
| 650 |
|
2 |
|a Health Care Quality, Access, and Evaluation.
|
| 650 |
|
2 |
|a Quality Assurance, Health Care
|
| 650 |
|
2 |
|a Technology, Industry, and Agriculture.
|
| 650 |
|
2 |
|a Statistics as Topic
|
| 650 |
|
2 |
|a Professional Practice
|
| 650 |
|
2 |
|a Public Health
|
| 650 |
|
2 |
|a Natural Science Disciplines
|
| 650 |
|
2 |
|a Health Care Evaluation Mechanisms
|
| 650 |
|
2 |
|a Named Groups.
|
| 650 |
|
2 |
|a Financing, Organized
|
| 650 |
|
2 |
|a Humanities
|
| 650 |
|
2 |
|a Sexually Transmitted Diseases
|
| 650 |
|
2 |
|a Chemicals and Drugs.
|
| 650 |
|
2 |
|a Epidemiologic Methods
|
| 650 |
|
2 |
|a Virus Diseases
|
| 650 |
|
2 |
|a Policy
|
| 650 |
|
2 |
|a Psychiatry and Psychology.
|
| 650 |
|
6 |
|a Médicaments contre le sida
|x Aspect social
|z États-Unis
|v Congrès.
|
| 650 |
|
6 |
|a Pharmacologie expérimentale
|x Aspect social
|z États-Unis
|v Congrès.
|
| 650 |
|
6 |
|a Infections à VIH
|x Chimiothérapie
|x Aspect social
|z États-Unis
|v Congrès.
|
| 650 |
|
6 |
|a Comités d'éthique de la recherche.
|
| 650 |
|
6 |
|a Services de santé
|x Accessibilité.
|
| 650 |
|
6 |
|a Contrôle social.
|
| 650 |
|
6 |
|a Sida.
|
| 650 |
|
6 |
|a Enfants.
|
| 650 |
|
6 |
|a Gouvernement fédéral.
|
| 650 |
|
6 |
|a Expérimentation humaine en médecine.
|
| 650 |
|
6 |
|a Sélection de patients.
|
| 650 |
|
6 |
|a Recherche.
|
| 650 |
|
6 |
|a Risque.
|
| 650 |
|
6 |
|a Institutions politiques.
|
| 650 |
|
6 |
|a Infections à VIH.
|
| 650 |
|
6 |
|a Assurance-maladie.
|
| 650 |
|
6 |
|a Évaluation du risque.
|
| 650 |
|
6 |
|a Comités d'éthique.
|
| 650 |
|
6 |
|a Liberté.
|
| 650 |
|
6 |
|a Services d'information.
|
| 650 |
|
6 |
|a Femmes.
|
| 650 |
|
6 |
|a Soins médicaux.
|
| 650 |
|
6 |
|a Consentement éclairé (Droit médical)
|
| 650 |
|
6 |
|a Minorités.
|
| 650 |
|
6 |
|a Industrie pharmaceutique.
|
| 650 |
|
6 |
|a Méthodologie.
|
| 650 |
|
6 |
|a Économie politique.
|
| 650 |
|
6 |
|a Droits de l'homme (Droit international)
|
| 650 |
|
6 |
|a Sociologie.
|
| 650 |
|
6 |
|a Probabilités.
|
| 650 |
|
6 |
|a Industrie.
|
| 650 |
|
6 |
|a Maladies à virus lents.
|
| 650 |
|
6 |
|a Organisations non gouvernementales.
|
| 650 |
|
6 |
|a Prestation de soins.
|
| 650 |
|
6 |
|a Sciences.
|
| 650 |
|
6 |
|a Services de santé.
|
| 650 |
|
6 |
|a Médicaments.
|
| 650 |
|
6 |
|a Services de santé
|x Administration.
|
| 650 |
|
6 |
|a Communication.
|
| 650 |
|
6 |
|a Syndromes de déficit immunitaire.
|
| 650 |
|
6 |
|a Gestion du risque.
|
| 650 |
|
6 |
|a Infections à lentivirus.
|
| 650 |
|
6 |
|a Sciences sociales.
|
| 650 |
|
6 |
|a Assurance.
|
| 650 |
|
6 |
|a Thérapeutique.
|
| 650 |
|
6 |
|a Soins médicaux
|x Qualité
|x Contrôle.
|
| 650 |
|
6 |
|a Statistiques.
|
| 650 |
|
6 |
|a Pratique professionnelle.
|
| 650 |
|
6 |
|a Santé publique.
|
| 650 |
|
6 |
|a Sciences physiques.
|
| 650 |
|
6 |
|a Sciences humaines.
|
| 650 |
|
6 |
|a Infections transmissibles sexuellement.
|
| 650 |
|
6 |
|a Maladies à virus.
|
| 650 |
|
7 |
|a children (people by age group)
|2 aat
|
| 650 |
|
7 |
|a federal government.
|2 aat
|
| 650 |
|
7 |
|a research (function)
|2 aat
|
| 650 |
|
7 |
|a governments (administrative bodies)
|2 aat
|
| 650 |
|
7 |
|a risk assessment.
|2 aat
|
| 650 |
|
7 |
|a freedom.
|2 aat
|
| 650 |
|
7 |
|a minorities.
|2 aat
|
| 650 |
|
7 |
|a methodology.
|2 aat
|
| 650 |
|
7 |
|a economics.
|2 aat
|
| 650 |
|
7 |
|a sociology.
|2 aat
|
| 650 |
|
7 |
|a probability.
|2 aat
|
| 650 |
|
7 |
|a sciences (philosophy)
|2 aat
|
| 650 |
|
7 |
|a risk management.
|2 aat
|
| 650 |
|
7 |
|a social sciences.
|2 aat
|
| 650 |
|
7 |
|a insurance.
|2 aat
|
| 650 |
|
7 |
|a public health.
|2 aat
|
| 650 |
|
7 |
|a physical sciences.
|2 aat
|
| 650 |
|
7 |
|a humanities.
|2 aat
|
| 650 |
|
7 |
|a MEDICAL
|x AIDS & HIV.
|2 bisacsh
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x AIDS & HIV.
|2 bisacsh
|
| 650 |
|
7 |
|a Pharmacology, Experimental
|x Social aspects.
|2 fast
|0 (OCoLC)fst01060281
|
| 651 |
|
7 |
|a United States.
|2 fast
|0 (OCoLC)fst01204155
|
| 650 |
|
7 |
|a Infections à VIH.
|2 fmesh
|
| 650 |
|
7 |
|a Syndrome d'immunodéficience acquise.
|2 fmesh
|
| 655 |
|
2 |
|a Congress
|
| 655 |
|
7 |
|a Conference papers and proceedings.
|2 fast
|0 (OCoLC)fst01423772
|
| 655 |
|
7 |
|a Conference papers and proceedings.
|2 lcgft
|
| 655 |
|
7 |
|a Actes de congrès.
|2 rvmgf
|
| 710 |
2 |
|
|a Roundtable for the Development of Drugs and Vaccines against AIDS (Institute of Medicine)
|
| 776 |
0 |
8 |
|i Print version:
|a Nichols, Eve K.
|t Expanding access to investigational therapies for HIV infection and AIDS.
|d Washington, D.C. : National Academy Press, 1991
|z 0309044901
|w (DLC) 91060585
|w (OCoLC)23661748
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=14262
|z Texto completo
|
| 938 |
|
|
|a EBL - Ebook Library
|b EBLB
|n EBL3375988
|
| 938 |
|
|
|a ebrary
|b EBRY
|n ebr10054979
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 14262
|
| 938 |
|
|
|a ProQuest MyiLibrary Digital eBook Collection
|b IDEB
|n 20356
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 2309844
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 6012552
|
| 938 |
|
|
|a Internet Archive
|b INAR
|n expandingaccesst0000nich
|
| 994 |
|
|
|a 92
|b IZTAP
|
